PMID- 26164828
OWN - NLM
STAT- MEDLINE
DCOM- 20151208
LR  - 20160217
IS  - 1879-1891 (Electronic)
IS  - 0002-9394 (Linking)
VI  - 160
IP  - 4
DP  - 2015 Oct
TI  - Spectral-Domain Optical Coherence Tomography of Subretinal Hyperreflective 
      Exudation in Myopic Choroidal Neovascularization.
PG  - 749-58.e1
LID - S0002-9394(15)00390-6 [pii]
LID - 10.1016/j.ajo.2015.07.004 [doi]
AB  - PURPOSE: To study the effect of anti-vascular endothelial growth factor (VEGF) 
      therapy on subretinal hyperreflective exudation detected by spectral-domain 
      optical coherence tomography (SD OCT) in myopic choroidal neovascularization 
      (CNV). DESIGN: Retrospective consecutive observational cohort study. METHODS: 
      Thirty-one eyes of 31 consecutive highly myopic patients with CNV and showing a 
      subretinal hyperreflective exudation on SD OCT were included. Morphologic changes 
      were assessed before and after anti-VEGF therapy, based on the subretinal 
      hyperreflective exudation thickness, retinal thickness at the level of the CNV, 
      and central macular thickness. RESULTS: After anti-VEGF treatment (mean follow-up 
      of 1.9 +/- 0.8 months, mean number of injections 1.8 +/- 0.6), the subretinal 
      hyperreflective exudation regressed completely in 29 of 31 eyes (93.5%) and 
      partially in 2 of 31 eyes (6.5%). Mean subretinal hyperreflective exudation 
      thickness, mean retinal thickness at the level of the CNV, and mean central 
      macular thickness significantly decreased from 102 +/- 50 mum to 2.6 +/- 10.2 mum (P < 
      .0001), from 419 +/- 99 mum to 312 +/- 64 mum (P < .0001), and from 361 +/- 69 mum to 326 
      +/- 72 mum (P = .0008), respectively. CONCLUSION: The subretinal hyperreflective 
      exudation was an SD OCT finding that correlated with signs of active myopic CNV 
      (either subretinal fluid/intraretinal cysts on SD OCT or dye leakage on 
      fluorescein angiography) and responded to treatment with anti-VEGF agents. The 
      presence of a subretinal hyperreflective exudation on SD OCT could help in making 
      decisions on the need to perform or not perform fluorescein angiography, and 
      regarding treatment or retreatment.
CI  - Copyright (c) 2015 Elsevier Inc. All rights reserved.
FAU - Bruyere, Elsa
AU  - Bruyere E
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France.
FAU - Caillaux, Violaine
AU  - Caillaux V
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France.
FAU - Cohen, Salomon Yves
AU  - Cohen SY
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France.
FAU - Martiano, David
AU  - Martiano D
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France.
FAU - Ores, Raphaelle
AU  - Ores R
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France.
FAU - Puche, Nathalie
AU  - Puche N
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France.
FAU - Souied, Eric H
AU  - Souied EH
AD  - Centre Hospitalier Intercommunal de Creteil, CRC, Paris Est Creteil University, 
      Creteil, France. Electronic address: eric.souied@chicreteil.fr.
LA  - eng
PT  - Journal Article
PT  - Observational Study
PT  - Research Support, Non-U.S. Gov't
DEP - 20150708
PL  - United States
TA  - Am J Ophthalmol
JT  - American journal of ophthalmology
JID - 0370500
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
SB  - IM
CIN - Am J Ophthalmol. 2015 Dec;160(6):1313-4. PMID: 26422830
CIN - Am J Ophthalmol. 2015 Dec;160(6):1314-5. PMID: 26572728
MH  - Aged
MH  - Angiogenesis Inhibitors/*therapeutic use
MH  - Blood-Retinal Barrier
MH  - Capillary Permeability
MH  - Choroidal Neovascularization/diagnosis/drug therapy/*physiopathology
MH  - Female
MH  - Fluorescein Angiography
MH  - Humans
MH  - Intravitreal Injections
MH  - Male
MH  - Middle Aged
MH  - Myopia, Degenerative/diagnosis/drug therapy/*physiopathology
MH  - Retrospective Studies
MH  - Subretinal Fluid/*physiology
MH  - *Tomography, Optical Coherence
MH  - Vascular Endothelial Growth Factor A/*antagonists & inhibitors
EDAT- 2015/07/15 06:00
MHDA- 2015/12/15 06:00
CRDT- 2015/07/13 06:00
PHST- 2015/02/07 00:00 [received]
PHST- 2015/07/01 00:00 [revised]
PHST- 2015/07/02 00:00 [accepted]
PHST- 2015/07/13 06:00 [entrez]
PHST- 2015/07/15 06:00 [pubmed]
PHST- 2015/12/15 06:00 [medline]
AID - S0002-9394(15)00390-6 [pii]
AID - 10.1016/j.ajo.2015.07.004 [doi]
PST - ppublish
SO  - Am J Ophthalmol. 2015 Oct;160(4):749-58.e1. doi: 10.1016/j.ajo.2015.07.004. Epub 
      2015 Jul 8.